Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians
- 1 August 2015
- journal article
- case report
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 13 (4) , e305-e309
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancerBone, 2013
- Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate CancerJournal of Clinical Oncology, 2012
- Bisphosphonates: The first 40yearsBone, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget’s diseaseJournal of Bone and Mineral Metabolism, 2010
- Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone diseaseProstate Cancer and Prostatic Diseases, 2008
- A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study AnalysisClinical Cancer Research, 2007
- Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate CancerClinical Cancer Research, 2006
- Prolonged Hypocalcemia After Treatment With Zoledronic Acid in a Patient With Prostate Cancer and Vitamin D DeficiencyJournal of Clinical Oncology, 2004